These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38788299)

  • 1. Application and challenges of nitrogen heterocycles in PROTAC linker.
    Li Y; Qu J; Jiang L; Peng X; Wu K; Chen M; Peng Y; Cao X
    Eur J Med Chem; 2024 Jul; 273():116520. PubMed ID: 38788299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel approaches for the rational design of PROTAC linkers.
    Zagidullin A; Milyukov V; Rizvanov A; Bulatov E
    Explor Target Antitumor Ther; 2020; 1(5):381-390. PubMed ID: 36046487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current strategies for the design of PROTAC linkers: a critical review.
    Troup RI; Fallan C; Baud MGJ
    Explor Target Antitumor Ther; 2020; 1(5):273-312. PubMed ID: 36046485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D based generative PROTAC linker design with reinforcement learning.
    Li B; Ran T; Chen H
    Brief Bioinform; 2023 Sep; 24(5):. PubMed ID: 37670499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure and Stability of Aromatic Nitrogen Heterocycles Used in the Field of Energetic Materials.
    Zong HH; Yao C; Sun CQ; Zhang JG; Zhang L
    Molecules; 2020 Jul; 25(14):. PubMed ID: 32679862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E3 ligase ligand optimization of Clinical PROTACs.
    Jiang H; Xiong H; Gu SX; Wang M
    Front Chem; 2023; 11():1098331. PubMed ID: 36733714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linkers as Game-changers in PROTAC Technology: Emphasizing General Trends in PROTAC Pharmacokinetics for their Rational Design.
    Cecchini C; Tardy S; Scapozza L
    Chimia (Aarau); 2022 Apr; 76(4):341-345. PubMed ID: 38069776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Review on Recent Advances in Nitrogen-Containing Molecules and Their Biological Applications.
    Kerru N; Gummidi L; Maddila S; Gangu KK; Jonnalagadda SB
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32326131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.
    Yokoo H; Tsuji G; Inoue T; Naito M; Demizu Y; Ohoka N
    Bioorg Chem; 2024 Apr; 145():107204. PubMed ID: 38377822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A beginner's guide to current synthetic linker strategies towards VHL-recruiting PROTACs.
    Zografou-Barredo NA; Hallatt AJ; Goujon-Ricci J; Cano C
    Bioorg Med Chem; 2023 Jun; 88-89():117334. PubMed ID: 37224698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Advancements in the Synthesis and Chemistry of Benzo-fused Nitrogen- and Oxygen-based Bioactive Heterocycles.
    Sharma R; Yadav RK; Sharma R; Sahu NK; Jain M; Chaudhary S
    Curr Top Med Chem; 2021 Oct; 21(17):1538-1571. PubMed ID: 34269667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
    Li X; Song Y
    J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitrogen-fused Heterocycles: Empowering Anticancer Drug Discovery.
    Biswas T; Mittal RK; Sharma V; Kanupriya ; Mishra I
    Med Chem; 2024; 20(4):369-384. PubMed ID: 38192143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PROTACs: A novel strategy for cancer drug discovery and development.
    Han X; Sun Y
    MedComm (2020); 2023 Jun; 4(3):e290. PubMed ID: 37261210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals.
    Vitaku E; Smith DT; Njardarson JT
    J Med Chem; 2014 Dec; 57(24):10257-74. PubMed ID: 25255204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent developments in the combinatorial synthesis of nitrogen heterocycles using solid phase technology.
    Chauhan PM; Srivastava SK
    Comb Chem High Throughput Screen; 2001 Feb; 4(1):35-51. PubMed ID: 11339216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Advances in PROTACs for Drug Targeted Protein Research.
    Yao T; Xiao H; Wang H; Xu X
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct functionalization of nitrogen heterocycles via Rh-catalyzed C-H bond activation.
    Lewis JC; Bergman RG; Ellman JA
    Acc Chem Res; 2008 Aug; 41(8):1013-25. PubMed ID: 18616300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microbial degradation of sulfur, nitrogen and oxygen heterocycles.
    Xu P; Yu B; Li FL; Cai XF; Ma CQ
    Trends Microbiol; 2006 Sep; 14(9):398-405. PubMed ID: 16860985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of Five-Membered Heterocycles in Human Histone Deacetylase Inhibitors.
    Frühauf A; Behringer M; Meyer-Almes FJ
    Molecules; 2023 Jul; 28(15):. PubMed ID: 37570656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.